|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||56.90 - 57.34|
|52 Week Range||30.00 - 57.76|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||58.92|
|Forward Dividend & Yield||0.62 (1.26%)|
|1y Target Est||N/A|
AstraZeneca (ZN) needs a blockbuster to justify its nearly $7 billion investment for a share of Japan-based Daiichi Sankyo's (TSE:4568) drug to treat a type of breast cancer. Warning! GuruFocus has detected 5 Warning Signs with AZN. The HER2-targeting antibody drug conjugate (ADC) and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with another drug combination.
AstraZeneca Plc’s first-ever stock sale has been a painful experience. The British drugmaker was exploiting its strong share price to get its financial house in order. Right now, its free cash flow isn’t enough to cover the dividend without some help from disposals.
Newer treatments such as lung cancer drug Tagrisso, now the company's top selling medicine, have helped the drugmaker's return to growth after years of crumbling sales due to patent losses on older drugs. Sales in China have shown explosive growth, more than doubling since 2012, but AstraZeneca executives on Friday said that may not be sustained. "The enormous growth you currently see in China, 28 percent, probably is not sustainable, but we feel very bullish that the growth will continue to be at a pace of between 15 percent and 20 percent," Ruud Dobber, executive vice president, BioPharma, told Reuters.
British drugmaker AstraZeneca Plc's first-quarter product sales beat analysts' expectations on Friday, benefiting from higher demand for its cancer medicines. Product sales rose 14 percent at constant ...
Moody's Investors Service says that Daiichi Sankyo Company, Limited's (A2 stable) announced collaboration with AstraZeneca PLC (A3 stable) on Daiichi Sankyo's trastuzumab deruxtecan (DS-8201) breast cancer drug is beneficial to the growth of the Japanese company's oncology franchise. On 29 March, Daiichi Sankyo announced the collaboration with AstraZeneca on the global development and commercialization of DS-8201, the most promising drug in Daiichi Sankyo's pipeline.
Moody's Investors Service (Moody's) has today affirmed AstraZeneca PLC's (AstraZeneca) A3 senior unsecured rating, its (P)A3 senior unsecured medium-term note program rating, its (P)A3 senior unsecured shelf rating and the short-term rating commercial paper at P-2. Concurrently, Moody's affirmed Zeneca Wilmington Inc.'s A3 senior unsecured rating.
Daiichi announced late Thursday that it has entered into a global development and collaboration agreement with AstraZeneca regarding its lead antibody drug conjugate [fam-] trastuzumab deruxtecan, or DS-8201. The drug is an investigational candidate that is being developed for multiple HER2-expressing cancers, including breast and gastric cancer, and additional development in non-small cell lung and colorectal cancer.
The deal on the drug known as trastuzumab deruxtecan sent shares in Japan's Daiichi soaring 16 percent, its daily limit, to a record high on Friday. Daiichi's stock has climbed 45 percent this year on optimism about the treatment. Britain's AstraZeneca plans to use some of the proceeds of a $3.5 billion share issue to fund the deal.
LONDON (AP) — Shares in drug maker Daiichi Sankyo soared after AstraZeneca agreed to pay the Japanese company up to $6.9 billion as part of an agreement to develop and market a potentially "transformative" cancer treatment.
shares traded near the bottom of the London market Friday after the drugmaker agreed a potential $6.9 billion deal with Japan's Daiichi Sankyo Co. to develop and market a breast and gastric cancer treatment over the coming years. AstraZeneca will pay Daiichi, with whom it has a prior agreement to market the constipation drug Movantik, around $1.35 billion upfront, with incentives and targets pegged at $5.55 billion, for shared worldwide costs and profits for the drug, known as trastuzumab deruxtecan. "We believe that trastuzumab deruxtecan could become a transformative new medicine for the treatment of HER2-positive breast and gastric cancers," said CEO Pascal Soriot.
The answer is found in AstraZeneca Plc’s $6.9 billion oncology tie-up with Japan’s Daiichi Sankyo Co. Ltd. The partnership is AstraZeneca’s biggest in more than a decade. A couple of years ago, the drugmaker was linked to a possible takeover of Daiichi, a deal that would have been a stretch even then.
Japan's Nikkei rose on Friday on optimism about the latest round of U.S.-China trade talks, with cyclical sectors such as shipping and machinery advancing on the last day of the Japanese fiscal year. Daiichi Sankyo Co grabbed the spotlight with a 16 percent jump to a daily-limit and record high of 5,100 yen.
Japan's Nikkei rose on Friday on optimism about the latest round of U.S.-China trade talks, with cyclical sectors such as shipping and machinery advancing on the last day of the fiscal year. Daiichi Sankyo Co was in focus, jumping 16 percent to a daily-limit high of 5,100 yen after the drugmaker and AstraZeneca Plc have signed a potential multibillion-dollar collaboration to develop and sell Daiichi's cancer drug trastuzumab deruxtecan.
British drugmaker AstraZeneca Plc said late on Thursday it entered into a collaboration deal with Daiichi Sankyo Co Ltd of Japan to develop trastuzumab deruxtecan, a proprietary antibody-drug conjugate ...
Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters. Japan's No.4 drugmaker by revenue has been focused on developing cancer treatments to offset a revenue drop following patent expirations of its mainstay high blood pressure drug. It is considering selling the Daiichi Sankyo Healthcare unit, four people told Reuters, declining to be identified as the information has not been made public.
Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters. Japan's fourth-largest drug maker by revenue has been focused on developing cancer treatments to offset a decline in revenue following patent expirations of its mainstay high blood pressure drug. It is considering selling the Daiichi Sankyo Healthcare unit, four people familiar with the matter told Reuters, declining to be identified because the information has not been made public.
Exelixis will receive a $20 million payout after Japanese partner Daiichi Sankyo gained approval for a hypertension treatment — prodding Exelixis stock to hit an eight-month high Tuesday.
MUNICH , January 7, 2019 /PRNewswire/ -- Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and ...
Cash-strapped Fortis accepted IHH'S investment offer in July after an extended bidding war for control of the company which operates about 30 private hospitals in India. Under the deal, IHH will pay Fortis 40 billion rupees for 31 percent stake, and then bid for another 26 percent as per Indian regulations, offering up to 33 billion rupees. The Supreme Court on Friday ordered status quo be maintained with regard to sale of the controlling stake in Fortis, after Japan's Daiichi Sankyo Co Ltd filed a contempt plea against Fortis founders Malvinder Singh and Shivinder Singh, according to a CNBC TV18 report.
Cash-strapped Fortis, which operates about 30 private hospitals in India, accepted an investment offer from IHH in July after an extended bidding war for control of the company. Japanese pharmaceutical firm Daiichi Sankyo Co Ltd had moved to Supreme Court filing a contempt plea against Malvinder and Shivinder Singh, alleging that they created encumbrances on 1.2 million shares of Fortis in violation of court orders, the CNBC TV18 report added. Reuters could not reach the Singh brothers for comment, while Fortis and Daiichi did not immediately respond to request for a comment.
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation TOKYO , Nov. 19, 2018 /PRNewswire/ -- Daiichi Sankyo (JP: 4568.T, ...
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event TOKYO , Nov. 8, 2018 /PRNewswire/ -- Daiichi Sankyo ( Japan : 4568.T, OTC: DSNKY) ...